Hemorrhage
Pipeline by Development Stage
Drug Modality Breakdown
Competitive Landscape
12 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 18 trials with date data
Clinical Trials (18)
Total enrollment: 6,487 patients across 18 trials
A Study to Compare the Efficacy and Safety of TachoSil and Surgicel Original as an Adjunct to Control Mild to Moderate Soft Tissue Bleeding During Surgery
This Study Looks at the Effects of Idarucizumab in Patients Who Take Dabigatran and Need Emergency Surgery or Are Bleeding
Reversal Dabigatran Anticoagulant Effect With Idarucizumab
CU Programme of Idarucizumab for Japanese Patients
Reversal of Dabigatran Anticoagulant Effect With Idarucizumab
TachoSil® Versus Surgicel® Original for the Secondary Treatment of Local Bleeding in Adult and Pediatric Patients Undergoing Hepatic Resection Surgery
Changes in Hemorrhage With Prophylactic Oxytocin for Dilation and Evacuation
Safety, Tolerability, PK and PD of BI 655075 and Establishment of BI 655075 Dose(s) Effective to Reverse Prolongation of Blood Coagulation Time by Dabigatran
Retrospective Study on Characteristics and Outcomes in Hospitalised Patients Treated With Ondexxya
EmboCube Gelatin Embolization to Control Bleeding or Hemorrhaging
Observational Study to Evaluate Safety of Idarucizumab in Pediatric Patients
All-Case Surveillance of Prizbind®
NIRS Monitoring in Premature Infants
An Observational Cohort Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding
Comparison of Physiological Variables During Blood Donation
Non-invasive Hemodynamic Monitoring During Blood Donation for Developing Models of Early Blood Loss
Infrahepatic Inferior Vena Cava Clamping During Hepatectomy
RCT of Zhi Byed 11 (ZB11) Versus Misoprostol in Tibet
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.